home / stock / hepa / hepa news

HEPA News and Press, Hepion Pharmaceuticals Inc. From 06/28/22

Stock Information
Company Name: Hepion Pharmaceuticals Inc.
Stock Symbol: HEPA
Market: NASDAQ
Website: hepionpharma.com
Menu
HEPA HEPA Quote HEPA Short HEPA News HEPA Articles HEPA Message Board
Get HEPA Alerts

News, Short Squeeze, Breakout and More Instantly...
HEPA - Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“...
HEPA - Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“...

HEPA - Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma

EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“...

HEPA - VBI Vaccines, Hepion win FDA Orphan Drug Designations for cancer candidates

VBI Vaccines (NASDAQ:VBIV) and Hepion Pharmaceuticals (HEPA) are trading sharply higher on Friday after the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designations for two of thier cancer candidates. According to a federal register, the FDA has granted the designation for a b...
HEPA - Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress(TM) 2022

- Hepion Represented as Authors in Preclinical and Clinical Posters Related to Rencofilstat and Cyclophilins – EDISON, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial In...

HEPA - Dr. Launa J. Aspeslet is the new chief of operations at Hepion Pharmaceuticals

Hepion Pharmaceuticals (NASDAQ:HEPA) appoints accomplished life sciences industry veteran, Launa J. Aspeslet, PhD, RAC, as COO. Most recently Dr. Aspeslet served as the CEO of Translational Research in Oncology. For further details see: Dr. Launa J. Aspeslet is the new ch...

HEPA - Hepion Pharmaceuticals Appoints Accomplished Life Sciences Industry Veteran, Dr. Launa J. Aspeslet, as Chief Operating Officer

- Dr. Aspeslet joins the Company to support rencofilstat’s clinical program - EDISON, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-drive...
HEPA - Hepion Pharmaceuticals Urges Shareholders to Vote "FOR" All Proposals Ahead of its Upcoming Annual Meeting

EDISON, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH&...

HEPA - CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc.

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- In the press release issued earlier today by Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), we've been informed by the company that in both the headline and first paragraph the name 'Recofilstat' should be 'Rencofilstat'. Completed corrected ...

HEPA - Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH&...
Previous 10 Next 10